0000000000342401

AUTHOR

Emil C. Reisinger

showing 3 related works from this author

Plasmodium falciparumMalaria: Reduction of Endothelial Cell Apoptosis In Vitro

2005

ABSTRACTOrgan failure inPlasmodium falciparummalaria is associated with neutrophil activation and endothelial damage. This study investigates whether neutrophil-induced endothelial damage involves apoptosis and whether it can be prevented by neutralization of neutrophil secretory products. Endothelial cells from human umbilical veins were coincubated with neutrophils from healthy donors and with sera from eight patients withP. falciparummalaria, three patients withP. vivaxmalaria, and three healthy controls. Endothelial apoptosis was demonstrated by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) and annexin V staining. The rate of apoptosis of cells was …

Umbilical VeinsProgrammed cell deathEndotheliumNeutrophilsPlasmodium falciparumImmunologyApoptosisBiologyMicrobiologyAntioxidantsAnnexinparasitic diseasesmedicineAnimalsHumansProtease InhibitorsMalaria FalciparumCells CulturedTUNEL assayImmune SeraEndothelial CellsPlasmodium falciparummedicine.diseaseAscorbic acidbiology.organism_classificationEndothelial stem cellInfectious Diseasesmedicine.anatomical_structureImmunologyParasitologyEndothelium VascularFungal and Parasitic InfectionsMalariaInfection and Immunity
researchProduct

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial.

2015

Antibiotic-associated diarrhea is an important clinical problem, associated with morbidity, mortality and healthcare costs. Our randomized, placebo controlled multicenter trial do not support the efficacy of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea.

0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationPlacebo-controlled studyPlacebolaw.inventionMajor Articles03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdverse effecteducationeducation.field_of_studybiologybusiness.industrybiology.organism_classificationClostridium difficile-associated diarrheaDiscontinuationSurgerySaccharomyces boulardiiInfectious DiseasesOncologyantibiotic-associated diarrhearandomized controlled trial030211 gastroenterology & hepatologyAntibiotic-associated diarrheabusinessprobioticSaccharomyces boulardiiOpen forum infectious diseases
researchProduct

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

2017

Summary Background Lyme borreliosis develops in 1–5% of individuals bitten by ticks, but with a diagnostic gap affecting up to 30% of patients, a broadly applicable pharmacological prevention strategy is needed. Topical azithromycin effectively eradicated Borrelia burgdorferi sensu lato from the skin in preclinical studies. We assessed its efficacy in human beings. Methods In this randomised, double-blind, placebo-controlled, multicentre trial done in 28 study sites in Germany and Austria, adults were equally assigned to receive topical 10% azithromycin or placebo twice daily for 3 consecutive days, within 72 h of a tick bite being confirmed. Randomisation numbers, which were stratified by …

AdultMale0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationAzithromycinAzithromycinPlacebolaw.invention03 medical and health sciencesTicksDouble-Blind MethodRandomized controlled triallawGermanyInternal medicinemedicineClinical endpointAnimalsHumansTreatment FailureSeroconversioneducationLyme Diseaseeducation.field_of_studybusiness.industryAntibiotic ProphylaxisMiddle Agedbacterial infections and mycosesAnti-Bacterial AgentsSurgeryClinical trialInfectious DiseasesBorrelia burgdorferiErythema migransFemalebusinessmedicine.drugThe Lancet Infectious Diseases
researchProduct